JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals

Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates (ADCs).

“Building a world-class oncology organization, we obviously want to continue to make sure we not only compare the best opportunities internally, but also externally,” Pfizer’s newly minted chief oncology officer, Chris Boshoff, Ph.D., said in an interview on the sidelines of the J.P. Morgan Healthcare Confernece.